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ORIGINAL ARTICLELaboratory-based surveillance of pertussis using multitarget real-time PCR
in Japan: evidence for Bordetella pertussis infection in preteens and teensK. Kamachi1, S. Yoshino2, C. Katsukawa3, N. Otsuka1, Y. Hiramatsu1 and K. Shibayama1
1) Department of Bacteriology II, National Institute of Infectious Disease, Tokyo, 2) Department of Microbiology, Miyazaki Prefectural Institute for Public Health
and Environment, Miyazaki and 3) Department of Infectious Diseases, Osaka Prefectural Institute of Public Health, Osaka, JapanAbstractBetween January 2013 and December 2014, we conducted laboratory-based surveillance of pertussis using multitarget real-time PCR, which
discriminates among Bordetella pertussis, Bordetella parapertussis, Bordetella holmesii and Mycoplasma pneumoniae. Of 355 patients clinically
diagnosed with pertussis in Japan, B. pertussis, B. parapertussis and M. pneumoniae were detected in 26% (n = 94), 1.1% (n = 4) and 0.6%
(n = 2), respectively, whereas B. holmesii was not detected. It was conﬁrmed that B. parapertussis and M. pneumoniae are also responsible
for causing pertussis-like illness. The positive rates for B. pertussis ranged from 16% to 49%, depending on age. Infants aged  3 months
had the highest rate (49%), and children aged 1 to 4 years had the lowest rate (16%, p < 0.01 vs. infants aged  3 months). Persons aged
10 to 14 and 15 to 19 years also showed high positive rates (29% each); the positive rates were not statistically signiﬁcant compared
with that of infants aged  3 months (p  0.06). Our observations indicate that similar to infants, preteens and teens are at high risk of
B. pertussis infection.
New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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E-mail: kamachi@nih.go.jpIntroductionPertussis (whooping cough) is a major acute respiratory infec-
tion caused by Bordetella pertussis bacteria and is associated with
severe respiratory illness in children and persistent cough in
adolescents and adults. The most effective method to prevent
and control pertussis is immunization; however, the incidence
of pertussis has increased in several developed countries
despite high vaccination coverage [1]. Bordetella parapertussis
and Bordetella holmesii, which are closely related to B. pertussis,
also cause pertussis-like coughs [2,3]. Acellular pertussis vac-
cines (ACVs) have little or no protection against B. parapertussisw Microbe and New Infect 2015; 8: 70–74
w Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
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p://dx.doi.org/10.1016/j.nmni.2015.10.001and B. holmesii infections, both of which have been detected
recently with signiﬁcant percentages in pertussis-like illness
[4–6]. In addition, Mycoplasma pneumoniae is a bacterial agent
of atypical pneumonia in children and adults that also causes a
persistent pertussis-like cough [7]. The clinical diagnosis of
B. pertussis infection is complicated by other respiratory path-
ogens [8].
In Japan, the incidence of pertussis cases in adolescents and
adults has signiﬁcantly increased since the early 2000s, and a
large pertussis epidemic occurred between 2008 and 2010
despite high vaccination coverage with ACVs [9]. A total of
17 349 cases were reported from approximately 3000 sentinel
clinics and hospitals in the epidemic. The national pertussis
surveillance data regarding individuals diagnosed mainly on the
basis of clinical symptoms, bacterial culture and/or serologic
testing are collected. In comparison to culture and serology,
which are the classic tests for pertussis diagnosis, nucleic acid
ampliﬁcation tests have improved sensitivity and speciﬁcity;
however, these tests have not yet been widely introduced intoEuropean Society of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
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tory for pertussis, developed a multitarget real-time PCR assay
(4Plex RT-PCR) to discriminate among B. pertussis, B. para-
pertussis, B. holmesii and M. pneumoniae and then introduced the
assay into our diagnostic service starting in January 2013. The
present study reports 2 years of experience of the service for
355 patients with clinically suspected pertussis.Materials and MethodsClinical specimens
Between January 2013 and December 2014, we conducted a
laboratory-based surveillance study of 355 patients clinically
diagnosed with pertussis. Clinical specimens (nasopharyngeal
swab or aspirate) were collected at 19 medical institutions in
Japan. All the nasopharyngeal aspirates (2% of the total number
of specimens) were collected from young infants hospitalized
with severe respiratory distress. The specimens were trans-
ported to the National Institute of Infectious Diseases, Japan.
Nasopharyngeal swabs were immersed in 0.5 mL of saline,
vortexed and subjected to centrifugation (20 000 × g for 10
minutes). Nasopharyngeal aspirates (50–100 μL) were sus-
pended in 1 mL of saline, vortexed, and centrifuged at the same
conditions. Total DNA was extracted from the pellet using the
QIAamp DNA Micro kit (Qiagen) and eluted with 25 μL of the
AE elution buffer. If several specimens were received from a
single patient, they were tested separately. The overall result
was considered positive if any of these specimens tested
positive.
In Japan, pertussis cases are reported based on clinical
diagnosis. The clinical criteria are cough lasting for  2 weeks
with one or more of the following symptoms: whoop and
staccato cough, apneic paroxysm or posttussive vomiting.TABLE 1. Primers and probes used for 4Plex real-time PCR
Target gene (organism)
Primer or
probe Sequence (50 to 30)
IS481 (Bordetella pertussis and Bordetella
holmesii)
PPertM ATCAAGCACCGCTTTACCC
APPert TTGGGAGTTCTGGTAGGT
SPertM CAAGGCCGAACGCTTa
recA (B. holmesii) BHrecA-F CGGTTCGCTGGGTCTCG
BHrecA-R CCCGCGGCAGACCAC
BHrecA-P CATCGCATTGGGCG
IS1001 (B. parapertussis) PParaP GATATCAACGGGTGACGG
APParaP GTATGCCAACCCAGTTCG
SParaM TGCAATCGAGCAACGa
atpD (M. pneumoniae) Mp3-F CGATCTATGTGCCAGCTG
Mp3-R AGCATCCAGGTGGGTAAA
Mp3-P TTGACTGACCCCGCTCCG
aOligonucleotide length was modiﬁed.
bNon-Fluorescent Quencher-Minor Groove Binder.
cBlack Hole Quencher 3.
New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beha
This is an open access artiHowever, in the present study, patients were clinically diag-
nosed based on their physician’s judgement, so not all patients
met the reporting criteria.
This study was considered exempt from institutional review
board approval because clinical specimens were obtained for
diagnostic and surveillance purposes.
4Plex RT-PCR
Target sequences of the 4Plex RT-PCR were insertion
sequence IS481 (detection for B. pertussis and B. holmesii), recA
(B. holmesii), IS1001 (B. parapertussis) and atpD (M. pneumoniae).
Published primers and probes were used for recA and atpD
[10,11], and those for IS481 and IS1001 were used with minor
modiﬁcations [12] (Table 1). 4Plex RT-PCR was performed
using an ABI 7500 Fast Real-Time PCR System (Applied Bio-
systems). The PCR ampliﬁcations were carried out in 20 μL
reaction volumes containing 10 μL of 2× Premix EX Taq (Perfect
Real Time, Takara Bio), 0.2 μL of 50× ROX reference dye II,
2 μL of DNA samples and optimized concentrations of primers
and probes (Table 1). The PCR conditions were 10 s at 95°C,
followed by 40 cycles of 95°C for 3 seconds and 60°C for 30
seconds. The cutoff threshold ΔRn (relative ﬂuorescent in-
tensity) value was set to 0.3 for all ﬂuorescence signals, and the
sample was considered positive with a change in ΔRn of  0.3,
corresponding to a threshold cycle (CT) cutoff value of
approximately 36 with automatic calculation. In each assay,
puriﬁed DNAs (10 pg of B. pertussis Tohama, 100 pg of
B. holmesii ATCC51542, 10 pg of B. parapertussis BAA-587, 1 pg
of M. pneumoniae NBRC14401) were used as positive controls,
whereas the negative control was sterile distilled water. The
analytical sensitivities of the assay were not affected by multi-
plexing (Supplemental Fig. S1). The measured PCR ampliﬁcation
efﬁciencies of 98% to 103% for the targets B. holmesii IS481 and
recA and M. pneumoniae atpD were in good agreement with theReporter/
quencher
Amplicon
(bp)
Optimal concentration
(nM) Reference
Ga 114 300 [12]
GTG 300
FAM/NFQ-MGBb 200
50 400 [10]
400
VIC/NFQ-MGB 300
ATC 103 300 [12]
AA 300
NED/NFQ-MGB 100
ATGA 68 200 [11]
GGT 200
GC Cy5/BHQ3c 100
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FIG. 1. Monthly distribution of samples positive for Bordetella pertussis (BP), Bordetella parapertussis (BPP) and Mycoplasma pneumoniae (MP) between
January 2013 and December 2014 in Japan. A total of 355 patients were tested using 4Plex RT-PCR. Numbers of patients with positive and negative
results are shown by vertical bars (left y-axis). No samples were positive for Bordetella holmesii. Reported pertussis cases in Japan (national pertussis
surveillance data) are shown by purple line (right y-axis), with each value representing a week of the year. National surveillance data were obtained
from Infectious Disease Surveillance data of the Ministry of Health, Labor and Welfare of Japan. ND, not detected for any of the organisms.
72 New Microbes and New Infections, Volume 8 Number C, November 2015 NMNItheoretical value of 100%. The efﬁciencies for B. pertussis IS481
and B. parapertussis IS1001 showed somewhat higher values
(116–117%), the reason for which is currently unclear.
In the 4Plex RT-PCR assay, B. pertussis infection was deﬁned
as positive for IS481 and negative for recA (IS481+/recA−),
whereas B. holmesii was deﬁned as positive for both IS481 and
recA (IS481+/recA+). B. parapertussis and M. pneumoniae were
deﬁned as positive for IS1001 and atpD, respectively.
Statistical analysis
Data were analysed by Fisher’s exact test. A value of p < 0.05
was considered statistically signiﬁcant.ResultsAmong 355 patient samples, 94 (26%), four (1.1%) and two
(0.6%) were positive for B. pertussis, B. parapertussis and M.
pneumoniae, respectively. There was no incidence of coinfec-
tion with those organisms. No positive samples for B. holmesii
were detected, but 4Plex RT-PCR targeting recA is less sensitiveTABLE 2. Results of 4Plex real-time PCR for 355 patient samples c
Patient age range No. of samples tested
No. of positive results
Bordetella pertussis Bor
 3 months 43 21 −
4–11 months 42 11 −
1–4 years 70 11 3
5–9 years 76 20 1
10–14 years 51 15 −
15–19 years 21 6 −
 20 years 49 9 −
Unknown 3 1 −
Total 355 94 (26%) 4 (1
New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licethan IS481. Fig. 1 shows the monthly distribution of samples
testing positive using PCR. B. pertussis–positive samples were
observed in relatively large numbers from April to June 2014
(34% of the total) and also showed a tendency to decrease in
the winter season from December to February. Four
B. parapertussis–positive samples were detected in 2013. All of
them were collected in the same hospital, with no apparent
seasonal variations. Two M. pneumoniae–positive samples were
detected in October 2013 and 2014, and conﬁrmed using a
separate genetic test (Loopamp Mycoplasma P Detection Kit;
Eiken Chemical, Japan). Our pertussis surveillance data did not
fully correspond with national pertussis surveillance data,
especially in the period from April to August 2014.
As shown in Table 2, of 94 B. pertussis-positive samples, 21
were from infants aged  3 months, and 20 were from children
aged 5 to 9 years. Of four B. parapertussis-positive samples,
three and one were from children aged 1 to 4 years and 5 to 9
years, respectively. Similarly, two M. pneumoniae–positive
samples belonged to the same age groups. Fig. 2 shows positive
rates for B. pertussis by age group. Infants aged  3 months had
the highest rate (49%), whereas children aged 1 to 4 years hadollected between 2013 and 2014
detella parapertussis Bordetella holmesii Mycoplasma pneumoniae
− −
− −
− 1
− 1
− −
− −
− −
− −
.1%) 0 2 (0.6%)
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FIG. 2. Age distribution of PCR-positive rates for Bordetella pertussis.
Total of 93 patients of known age were classiﬁed into seven age groups
(Table 2). Statistically signiﬁcant differences (Fisher’s exact test) be-
tween infants aged  3 months (reference) and other age groups are
indicated by asterisks (*p < 0.05; **p < 0.01). Age groups not signiﬁ-
cantly different from reference group are indicated by NS. M, months;
Y, years.
NMNI Kamachi et al. Laboratory-based surveillance of pertussis 73the lowest rate (16%). Of note, the positive rates showed a
weak bimodal distribution by age group. The positive rates of
the age groups 4 to 11 months, 1 to 4 years, 5 to 9 years, and 
20 years were statistically lower than that of infants aged  3
months (p < 0.05, Fisher’s exact test). In contrast, the positive
rates of the age groups 10 to 14 and 15 to 19 years were not
statistically signiﬁcant with that of infants aged  3 months (p
0.06 and 0.18, respectively).DiscussionThis study conﬁrmed that B. pertussis is the most common
aetiologic agent in cases of suspected pertussis and that
B. parapertussis and M. pneumoniae are also responsible for
causing a small proportion of pertussis-like illnesses. In this
study, no positive samples for B. holmesii were detected,
although respiratory infection with B. holmesii has recently
increased worldwide [3,5,6]. 4Plex RT-PCR has high analytical
sensitivities for B. pertussis, B. parapertussis and M. pneumoniae
(detection limits of 10–100 fg genomic DNA), but it has a
relatively low sensitivity for B. holmesii recA (detection limit of
1 pg DNA, corresponding to a CT value of 35.6). We therefore
cannot exclude the possibility that some patients could have
low B. holmesii DNA loads (CT value of > 35.6) in their clinical
specimens. However, we previously reported that patients not
treated with antibiotics had high B. holmesii DNA loads (CT
values of 21.6 to 28.7) in their nasopharyngeal swab samples
[5]. Thus, 4Plex RT-PCR has sufﬁcient sensitivity to detect
B. holmesii in clinical specimens. A recent study has found that
an increasing number of B. holmesii bacteraemia cases were
associated with outbreaks of B. pertussis [13]. This suggests thatNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beha
This is an open access artiB. holmesii epidemics occur periodically, similar to B. pertussis. In
Japan, a B. pertussis epidemic has not occurred from 2011 to the
present; hence, continuous laboratory-based surveillance is
required for B. holmesii.
In the present study, B. pertussis–positive samples were
detected from individuals over a wide age range, consistent with
previous reports [14–17]. Infants aged  3 months had the
highest positive rate (49%); interestingly, persons aged 10 to 14
and 15 to 19 years also showed high positive rates (each 29%).
In Japan, ACVs are used to control pertussis with a schedule of
three primary doses and a single booster dose at ages 3, 4, 6
and 18 to 23 months, respectively. The vaccination is done
under the Japanese Preventive Vaccination Law, and conse-
quently immunization rates among children are high ( 90%).
The duration of immunity after vaccination is estimated to be in
the range of 4 to 12 years [18,19]; accordingly, preteens and
teens are considered to be at high risk of B. pertussis infection.
Our data provide support for the waning immunity in the
second decade of life. Moreover, this study also demonstrates
that children aged 1 to 4 years had the lowest positive rate
(16%). This age group covers children from the age where they
have received at least three doses of ACVs. The herd immunity
against B. pertussis would be well maintained in the age group of
1 to 4 years. The lack of detailed clinical information (e.g.,
duration of cough, time of specimen collection and time of
onset of symptoms) makes it difﬁcult to explain why the
B. pertussis–positive rate is equally low (18%) in the  20 years
age group.
Recent genomic analyses revealed that some Bordetella
bronchiseptica isolates (a broad-host-range pathogen) harbor
IS481 and/or IS1001 [20]. This implies that B. bronchiseptica
cannot be discriminated from B. pertussis and B. parapertussis
using 4Plex RT-PCR. However, B. bronchiseptica infection in
humans is rare [21,22]; are only two case reports exist from
Japan. Therefore, we believe that B. bronchiseptica infection is
negligible in our results.
In conclusion, we successfully used 4Plex RT-PCR for the
surveillance of pertussis in Japan. Additionally, we conﬁrmed
that, similar to infants, preteens and teens are at high risk of
B. pertussis infection. The 4Plex RT-PCR described here has
become a practical tool for detection of pertussis, and there-
fore we have started supplying the 4Plex RT-PCR kit to Japa-
nese prefectural and municipal public institutes for regional
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